14
Participants
Start Date
June 30, 2004
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
rechargeable TANTALUS II
Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
Diabetes and Glandular Disease Clinic (DGD), San Antonio
Cedars Sinai, Los Angeles
MetaCure (USA), Inc.
INDUSTRY